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Abstract
Background and aims: NHS Tayside is a health board in Scotland which serves
around 400 000 residents. Approximately, 2761 are estimated to be persons who
inject drugs (PWID), and therefore at risk of infections such as hepatitis C (HCV) and
HIV. There are few studies exploring mechanisms and success of eliminating HCV in
HIV co-infected PWID using real-world data. This study aims to empirically assess
HCV treatment outcomes in people living with HIV (PLHIV) to evaluate progress
toward microelimination of HCV in the HIV-positive population in Tayside.
Methods: HCV testing and treatment details for PLHIV stored on clinical databases dating
from 2001 were extracted and anonymized. HCV treatment uptake among co-infected
patients eligible for HCV treatment was calculated. Reinfection incidence was calculated
in person years. Confidence intervals were calculated assuming Poisson distribution. Cal-
dicott Guardian approval was obtained to access patient data (ref: IGTCAL 5677).
Results: Ninety-six percent of PLHIV were tested for HCV across nine services and
aware of their HCV status. From 2001 to 2019, 58 PLHIV were HCV co-infected. Four
left the area and five died prior to HCV treatment. Forty-nine were eligible for HCV
treatment. Thirty were treated with PEGylated interferon (Peg-IFN); 18 with direct act-
ing antivirals (DAA). One is yet to be treated. Twelve treated with Peg-IFN did not
achieve sustained viral response (SVR12); 10 were retreated, two died prior to re-treat-
ment. Injecting drug use was the mode of HCV transmission for 39 of 49 patients. Pro-
portion who achieved SVR12 is 75%; 92% if treated with DAAs. Annual proportions of
PLHIV treated for HCV increased from 3.57% in the Peg-IFN era to 66.67% in the
DAA era. Reinfection incidence is 0.2 per 100 person years (CI −0.3 to 0.7).
Conclusions: NHS Tayside has made progress toward microelimination of HCV
among PLHIV. The most common mode of HCV transmission in PLHIV in NHS
Tayside is injecting drug use. DAAs increased the proportion of co-infected PLHIV
treated for HCV and produced superior SVR12 results compared to Peg-IFN.
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1 | INTRODUCTION
The World Health Organization (WHO) estimates that approximately
37 million people are living with HIV (PLHIV) globally; of these, 2.9 million
are co-infected with hepatitis C (HCV).1 The WHO urges that efforts to
effectively diagnose, treat, and link to care those people who are co-
infected are prioritized.2 In Scotland, of the estimated 4726 persons diag-
nosed with HIV, 565 (11.9%) have had a reactive HCV antibody (IgG) test,3
indicating that they have been exposed to HCV. Approximately, 0.3% of
the UK population4 and 1% of the Scottish population have been infected
with HCV5; this increases to 58% among people who inject drugs (PWID),
the highest risk group for transmission of HCV in Scotland.6
HCV prevalence is proportionally higher in HIV-positive individuals,
especially in PWID, than in HIV-negative individuals.7 Increased risk of nega-
tive health outcomes associated with HCV for those co-infected with HIV,
such as rapid acceleration of liver fibrosis,8 increased risk of hepatocellular
carcinoma,9 and mortality,10 over those mono-infected with HCV or HIV,
suggests the co-infected subgroup is a treatment priority. The British HIV
Association called for elimination of HCV in HIV patients by 2021.11 Further-
more, The Lancet: HIV asserts that, “because HIV and HCV share transmis-
sion pathways, targeted elimination, is an obvious and welcome synergy.”12
Using the WHO target of a 90% reduction in new chronic HCV infec-
tions, and a 65% reduction in liver-related deaths by 2030 as a guide,1 this
article investigates NHS Tayside's progress toward eliminating HCV among
PLHIV. Data presented here only represents the HIV-diagnosed population
living in the region, and any PLHIV who are/were unaware of their status
are not included in the analyses. However, Scotland has made strong pro-
gress on the UNAIDS 90-90-90 targets13 for PLHIV, with data indicating
that 91% of PLHIV in Scotland know their HIV status, 98% are on ART,
and 97% show evidence of viral suppression,14 so the proportion of
undiagnosed PLHIV in the region is likely to be low.
Tayside's population is relatively stable, and widely dispersed through
a mixture of rural towns and villages, to larger towns and cities across
approximately 3000 mile2. The integrated care pathway for blood-borne
viruses (BBV) has been developed to collocate HCV services where possi-
ble to overcome the barriers of population dispersion and geography. HCV
testing and treatment, including for PLHIV, is available through community
pharmacies, prison estates, substance misuse services, specialist clinics, gen-
eral practice (family practice), and injecting equipment provision sites
(Figure 1). The Health Board has been historically pro-active in testing and
treating for HCV among PLHIV in the region, with the goal of “micro-elimi-
nating”15 HCV within this population becoming more realistic with the
introduction of Direct Acting Antivirals (DAA) for HCV.
There are few studies exploring real-world mechanisms and suc-
cess rates of eliminating HCV in the HIV co-infected population whose
main risk factor is injecting drug use. Only one published study using
DAAs to eliminate HCV in HCV-HIV co-infected patients included
PWID.16 An ongoing prospective study in Australia is also examining
microelimination of HCV in a co-infected cohort of PWID.17 Two other
microelimination studies, one from the Netherlands,18 and a Swiss
treatment as prevention (TasP) study, examine HCV elimination among
HCV- HIV co-infected men who have sex with men (MSM).19
This descriptive cohort study aims to empirically assess HCV test-
ing and treatment outcomes for PLHIV in the NHS Tayside health
board, in the east of Scotland, to measure progress toward
microelimination of HCV among PLHIV in the region. The analyses are
further intended to review local practice, and document the
multi-stakeholder integrated care pathway for BBVs, which may be of
interest to other regions considering a HCV microelimination strategy.
2 | METHODS
2.1 | Study design
This is a descriptive cohort study. Caldicott Guardian20 approval was
obtained from NHS Tayside information governance services in order
for nominated individuals, who are members of the clinical care team for
PLHIV in NHS Tayside, to access the relevant clinical database/records for
the purposes of the study and create an anonymized database using Micro-
soft Excel 2013 (ref: IGTCAL 5677). This database was password protected
and stored on a secure, regularly backed-up server.
F IGURE 1 HCV testing and
treatment services in NHS
Tayside. GP, general practitioner;
HCV, hepatitis C virus;
IP, independent prescriber
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2.2 | Setting
NHS Tayside is a health board in Scotland serving some 400 000 peo-
ple, of which an estimated 2761 are current PWID (defined as self-
reported ever having injected drugs).
A team of infectious diseases physicians, trained HIV nurses, and
pharmacists care for all PLHIV, including PWID, in NHS Tayside using
an integrated care pathway. The HCV-HIV co-infected population are
managed by the infectious diseases team with input from hepatologists
via a weekly multi-disciplinary team meeting, and HCV specialist nurses
embedded in injecting equipment provision sites and opiate substitu-
tion therapy clinics. It is routine practice to screen PLHIV for hepatitis
B virus and HCV at initial contact with services. HCV testing is then
repeated annually in multiple settings (Figure 1) if there are ongoing risk
factors, or ad hoc if alanine transaminase is elevated (≥55 IU/L).
Depending on the setting, testing is either by venous blood sample or
dry blood spot test, which has been shown to be particularly effective
in testing PWID for HCV in Tayside and linking them to care.21
All routine virology testing for the region is performed in a central
laboratory, so all data from all known patients with HCV-HIV co-
infection in Tayside is routinely collected on an electronic clinical
database. Patient characteristics, test results, and treatments are
recorded by the treating physicians/healthcare staff.
2.3 | Participants
All adults (18 years or older) recorded on the NHS Tayside clinical
database with a diagnosis of HIV and a positive HCV result (IgG or
PCR) were screened initially for inclusion. Those with a positive HCV
IgG, but without positive HCV PCR test were excluded from the study
cohort. Those with both a diagnosis of HIV and a positive HCV PCR
test result were eligible for analysis and included in the final cohort.
Data were censored at October 31, 2019.
2.4 | Data sources
Data on: PWID in Tayside; prevalence of HCV among PWID; demo-
graphic data; laboratory results; imaging reports; and prescription
records were exported from the NHS Tayside clinical database. Data
on current HCV testing among PLHIV in NHS Tayside was obtained
from the NHS Tayside Public Health database. Once obtained, all data
was anonymized and saved to a password-protected Microsoft Excel
2013 workbook, stored on a secure NHS server. Patient identifiable
information was not utilized in the analysis.
2.5 | Statistical methods
Annual and cumulative treatment uptake was calculated for the
cohort eligible for HCV treatment (HCV PCR positive, alive, and resi-
dent in the area). Treatment outcome was defined as sustained viral
response at least 12 weeks post treatment (SVR12), virologic failure
(nonresponse or relapse), or nonvirologic failure (death, lost to follow
up or missing SVR12 data). If treated for HCV but death occurred prior
to SVR12 test, individuals were considered an unsuccessful treatment,
as it would have been inappropriate to include deceased individuals in
the cohort of successful treatments. Relapse is defined as
undetectable HCV RNA by the end of treatment, but detectable fol-
lowing treatment cessation. Nonresponse is a detectable HCV RNA
above the limit of detection (10 IU/mL) throughout treatment.
Reinfection was defined as quantifiable HCV RNA positivity after a
negative SVR12. Annual HCV RNA testing is offered to PLHIV cured
of HCV, but where a recent test was not available, the most recent
post-SVR12 test was used. Reinfection incidence was calculated in
person-years. Standard descriptive statistics were utilized. Confi-
dence intervals were calculated assuming the data arose from a




Between January 2001 and October 2019, 76 PLHIV were diagnosed
to have either past (HCV IgG positive, HCV RNA negative) or current
(HCV RNA positive) HCV in this cohort. Fifty-eight (76%) had current
HCV infection. Four (7%) moved from the area and five (9%) died prior
to commencing HCV therapy. This left 49 (84%) PLHIV who were
assessed and eligible for HCV treatment with the clinically favored
treatment method at time of assessment, based on their clinical char-
acteristics (eg, fibrosis markers, viral parameters, liver function tests,
safety bloodwork, HCV treatment history, HIV viral suppression). The
18 PLWH who were HCV IgG positive, PCR negative, were presumed
to have spontaneously cleared their HCV infection (Table 1).
Time of follow up was 372 person years (py; median follow up
time: 7 years, IQR 2,12). Five participants died during follow-up after
initial failed treatment (mortality rate 1.34 per 100 py; 95% CI
0.2-2.5) of which none were known to be liver related (mixed drug
overdose n = 2, unknown n = 3). Two patients were lost to follow-up
(0.54 per 100 py; 95% CI (−0.7-0.7): nonengager n = 1 and missing
post-treatment HCV RNA n = 1.
3.2 | Descriptive data
Individuals were predominantly male (n = 30, 61%). Mode of HCV
transmission, which is self-reported by patients to the treating physi-
cian and recorded on the clinical database, was documented as
injecting drug use (n = 39, 80%), heterosexual contact in female indi-
viduals (n = 5, 10%), migration from another country (n = 2, 4%), con-
taminated blood products (n = 2, 4%), and unknown (n = 1, 2%).
Median Fibroscan score for the analyzed cohort was 11.9, and
16 were diagnosed with cirrhosis (Fibroscan of ≥12.5 kPa; Table 1).
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3.3 | Main results
Of the 49 co-infected PLWH, 48 commenced HCV treatment,
44 achieved SVR12 and 5 died post-treatment (Figure 2).
Given the treatment period, most HCV treatments were with
Peg-IFN containing regimens (n = 30). Virologic or nonvirologic failure
occurred in 12/30 (40%) with Peg-IFN containing regimens, of those
nine (75%) had a second course of treatment to cure HCV, and all
obtained SVR12 (Figure 2, Table 2). The remaining three died before
they could be retreated.
Between 2001 and 2019, 10 people initiated more than one
course of HCV therapy. Nine were initially treated with Peg-IFN con-
taining regimens, while one had been treated with DAAs. All 10 indi-
viduals achieved SVR12 following retreatment.
Annual proportions of PLHIV diagnosed and treated for HCV
increased from 3.57% in the interferon era to 66.67% per year in the
interferon free DAA era (Table 3 and Figure 3). SVR12 was achieved in
all treated individuals in 2017, 2018, and 2019. Overall SVR12 for the
cohort is 75% (CI 63.9-83.1; 44/58 treatment courses). Proportion of
the cohort achieving SVR12 with DAA therapy, including treatment
experienced, was 92% (CI 81.8-102.2; 25/27 treatment courses). Only
one individual with known HCV-HIV coinfection is treatment naïve
and remains to be treated in Tayside, with efforts to engage them in
care ongoing. None of the remaining cohort of PLHIV alive and resi-
dent in Tayside require re-treatment for HCV at this time.
Reinfection was reported in one individual who initially attained
SVR12 following Peg-IFN based treatment who was subsequently suc-
cessfully retreated with DAAs. Reinfection incidence is calculated at
0.2 per 100 person years (CI −0.3 to 0.7) in the cohort.
Currently, 361 PLHIV receive HIV care in Tayside: 348 (96%)
have been HCV tested and are aware of their status; 13 (4%) have no
HCV test recorded. A total of 256 were tested through HIV clinics;
20 through hospital sexual health drop-in clinic; 19 through their GP;
15 as hospital inpatients; 11 in hospital outpatients; 2 in assistant con-
ception services; 2 in mental health services; 2 in maternity services;
and 1 in drug services. The source of 20 HCV tests were unclear.
4 | DISCUSSION
4.1 | Key results
The data presented here illustrate a long term, concerted multi-
stakeholder effort to microeliminate HCV infection among PLHIV in
NHS Tayside which, following introduction of DAAs, meets the
criteria set out in the guideline paper on microelimination of HCV.15
This study makes a novel contribution to the existing literature16-19
as it is a retrospective analysis of real-world outcomes which spans nearly
20 years, in persons whose most common mode of HCV transmission is
injecting drug use. This differs from published studies on microelimination
of HCV among PLHIV from Switzerland and the Netherlands18,19 which
are primarily focussed on MSM. Injecting drug use is recognized as a
major risk factor for HCV-HIV coinfection,22 and among PWID there is
considerable risk of reinfection with HCV post-SVR12.23 However, the
low incidence of HCV re-infection in this predominantly PWID cohort
suggests the general risk of HCV re-infection may be lower in PWID than
that observed in HCV-HIV co-infected MSM.18,24
The introduction of DAAs reduced the burden of HCV infection
among PLHIV from 2014 onward, similar to other findings,17 with
cumulative proportions of PLHIV co-infected with HCV both treated
and cured increasing compared to the Peg-IFN era (Table 3, Figure 3).
The overall SVR12 proportion for the cohort is perhaps somewhat
below what could be expected given published SVR rates in PWID in
excess of 90%.25-27 However, this can be explained by the relatively
higher number of Peg-IFN treatment observed. The DAA-only SVR12
rate is more in line with contemporary expectations.
Retreatment of individuals who became either reinfected with
HCV post-SVR12 or experienced virologic/nonvirologic failure was
evident in this cohort. Of the individuals who received more than one
course of HCV treatment, SVR12 was achieved in all instances of
retreatment. This demonstrates that individuals who have previously
undergone HCV treatment should be offered retreatment which is not
contingent on discriminatory parameters,28 especially in the context of
microelimination, and particularly given emerging evidence of successful
regimens for those who previously failed NS5A-containing regimens.29
TABLE 1 Demographic data for the cohort of PLHIV found to be




PLHIV and HCV IgG
positive (n = 76)






Characteristic HCV-HIV co-infected population
(n = 49)
On combination HIV therapy—
n (%)
49 (100)
Mode of HCV transmission—n
(%)
Injecting drug use 39 (80)






Median Fibroscan® score (IQR)
in KPa
11.9 (6.6-17.6)
Cirrhosis—n (%) 16 (33.3)
Abbreviations: HCV, hepatitis C virus; IQR, interquartile range;
IgG, immunoglobulin G; PLHIV, people living with HIV.
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NHS Tayside's integrated multistakeholder care pathway for HCV
among PLHIV has been key to progressing microelimination in this
cohort, with BBV tests being conducted in nine different services
(Figure 1). Integrating care pathways for HCV have been successful in
several discrete settings,30-32 and this study adds to the evidence for
co-location HCV care in related services at a regional level. Routine
HCV testing among PLHIV through diverse services ensures ongoing
monitoring of primary and reinfection.
The low loss to follow up in this cohort, and the willingness of
PLHIV to accept retreatment for HCV, indicates strong levels of
engagement and a trusting relationship with the clinical team among
PLHIV in NHS Tayside, factors recognized as essential to successful
management of chronic health conditions like HIV33 and HCV. The
real-world data presented here indicate that regional microelimination
of HCV-HIV coinfection can be advanced with an integrated model of
care, and HCV case-finding recommendations34 that encourage testing
and DAA treatment occurs close to the patient in community settings.
5 | LIMITATIONS
The clinical data analyzed in this study are generated from routine
clinical practice and therefore open to potential mischaracterization at
F IGURE 2 HCV treatment outcomes for
PLHIV in NHS Tayside 2001 to 2019.
HCV, hepatitis C virus; IgG, immunoglobulin G;
PCR, polymerase chain reaction; SVR, sustained
viral response
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the time of input by the healthcare staff recording the data. Any data
queries were addressed to staff who entered that data where possi-
ble. Where queries could not be resolved, data was presumed accu-
rately recorded. Cause of death could not be confirmed in three
individuals.
The study cohort is a small localized sample size, but is likely to
be representative of the wider HCV-HIV coinfected cohort in Scot-
land, or the United Kingdom, because of the population mix and
dispersion in the region. This cohort size may limit the generalizability
of the findings; especially for other cohorts of coinfected PLHIV who
may not have become infected with HCV via injecting drug use.
The study cohort may be biased toward those PLHIV who are
more likely to engage with healthcare services, and may not represent
the entire burden of HCV-infected PLHIV residing in NHS Tayside,
however, only small numbers of patients will not have presented to
services as a consequence of their HIV infection because access to
services is both comprehensive and community based. Furthermore,
Scotland has already attained UNAIDS 90-90-90 targets,14 indicating
the burden of unknown infection is likely to be low.
6 | INTERPRETATION
The data presented here show that there was an increase in the pro-
portion of coinfected individuals both initiating and successfully com-
pleting treatment for HCV after the introduction of DAAs in NHS
Tayside. Access to DAAs, and co-locating BBV services as part of a
multi-stakeholder strategy, substantially aided efforts to micro-
eliminate coinfection in the region, and should be considered
elsewhere.
Our data indicate that widespread, sustained and non-
discriminatory access to DAAs be prioritized for HCV-HIV co-infected
populations, including PWID and treatment-experienced individuals, if
WHO 2030 goals are to be realized. The high proportion of individuals
achieving a cure following retreatment indicates that it is feasible and
desirable to retreat HCV in co-infected PWID.
TABLE 2 HCV treatment uptake and outcomes among PLHIV in
NHS Tayside, 2001 to 2019
Interferon ± ribavirin
± 1st generation
DAA (n = 31)
Interferon-free




29 (93) 26 (96)
SVR 12—n (%) 19 (61) 25 (92)
Virological failure—n (%)
Non response 5 (16) 0
Relapse 4 (13) 1 (4)
Non virological failure—n (%)
Death 1 (3) 1 (4)
Lost to follow
up/missing SVR
1 (3) 1 (4)
Note: Data includes treatment naïve and treatment experienced.
Abbreviations: DAA, direct acting antivirals; PLHIV, people living with HIV;
SVR, sustained viral response.
F IGURE 3 Annual HCV diagnosis, treatment and cure in PLHIV in NHS Tayside 2001 to 2019. Note introduction of DAAs in 2014, and
decrease in diagnoses of new infections thereafter. DAA, direct acting antivirals; HCV, hepatitis C virus; Peg-IFN, pegylated interferon
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It is apparent that a co-located integrated care pathway can effec-
tively monitor for reinfection in defined geographic areas. Reinfection
incidence was low in this cohort, and testing rates are high among
PLHIV in NHS Tayside. The data presented here add to the evidence
supporting integration of BBV services when undertaking a HCV
microelimination strategy at a regional level.
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